Results 101 to 110 of about 1,772,527 (156)

DNA Methylation and Transcriptomic Profiles of Wilms Tumour Reveal New Deregulated Genes and Epigenetic Processes Relevant for Tumour Stratification and Management

open access: yesInternational Journal of Cancer, Volume 159, Issue 11, Page 2736-2754, 1 December 2026.
ABSTRACT Wilms Tumour (WT), the most common kidney cancer in children, presents features of altered kidney development and frequently exhibits molecular alterations at the 11p15.5 imprinted locus, affecting the IGF2 and H19 genes, which contribute to tumour growth and predisposition.
Abu Saadat   +14 more
wiley   +1 more source

Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy [PDF]

open access: yes
Altres ajuts: Cellex Foundation, CEL007; Asociación Española Contra el Cáncer, AC18/000002Alterations in epigenetic marks, such as DNA methylation, represent a hallmark of cancer that has been successfully exploited for therapy in myeloid malignancies ...
Molero, Antonieta   +34 more
core   +1 more source

Factors implicated in underutilization and poor persistence with hypomethylating agent therapy in myelodysplastic syndromes and chronic myelomonocytic leukaemia in Pakistan

open access: yesJournal of the Pakistan Medical Association
Objective: To assess the clinical and non-clinical factors leading to non-compliance or discontinuation of hypomethylating agent therapy in patients of myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Zoya Ziad   +6 more
doaj   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

open access: yesMolecular Oncology, Volume 20, Issue 11, Page 2584-2610, November 2026.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla   +4 more
wiley   +1 more source

Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML

open access: yes, 2018
Higher-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) of the elderly exhibit several commonalities, including first line treatment with hypomethylating agents (HMA) like azacitidine (AZA) or decitabine (DAC).
Uwe Platzbecker   +2 more
core   +1 more source

Epigenetic Reactivation of TNFRSF19 Suppresses Mitophagy and Sensitizes Triple‐Negative Breast Cancer to Doxorubicin

open access: yesAdvanced Science, Volume 13, Issue 64, 16 November 2026.
TNFRSF19 is an epigenetically silenced regulator of mitophagy in triple‐negative breast cancer. TNFRSF19 deficiency activates the TGFBR1–SMAD3–PINK1 axis to promote mitophagy and confer doxorubicin resistance, whereas decitabine‐mediated restoration of TNFRSF19 suppresses mitophagy and enhances doxorubicin sensitivity, revealing a targetable epigenetic–
Shiyang Liu   +7 more
wiley   +1 more source

Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial.

open access: yes
Primary endpoint treatment-change-free survival (TCFS), defined as time from randomization to death or initiation of a new disease-modifying treatment in the phase 2 DELTA trial. AML, acute myeloid leukemia; EPAG, eltrombopag; HMA, hypomethylating agents;
Sockel, Katja;Röllig, Christoph;Mütherig, Anke;Crysandt, Martina;Zukunft, Sven;Herbst, Regina;Noppeney, Richard;Schäfer-Eckardt, Kerstin;Kaufmann, Martin;Oelschlaegel, Uta;Fiebig, Frank;Giagounides, Aristoteles;Götze, Katharina;Scholl, Sebastian;Lück, Andreas;Rieger, Kathrin;Geer, Thomas;Kiewe, Philipp;Müller-Tidow, Carsten;Serve, Hubert;Baldus, Claudia D;Kaiser, Ulrich;Mahlmann, Stefan;Schmidt, Burkhard;Parmentier, Stefani;Illmer, Thomas;Seggewiss-Bernhardt, Ruth;Kiani, Alexander;Linde, Hartmut;Dürk, Heinz;Kramer, Michael;Kunadt, Desiree;Schmidt-Brücken, Katharina;Balaian, Ekaterina;Trautmann-Grill, Karolin;Ruhnke, Leo;Middeke, Jan Moritz;von Bonin, Malte;Ehninger, Gerhard;Thiede, Christian;Bornhäuser, Martin;Schetelig, Johannes;Platzbecker, Uwe
core   +1 more source

Outcomes of Venetoclax‐Based Regimens Versus Intensive and Reduced‐Intensity Chemotherapy in Newly Diagnosed AML

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Venetoclax‐based regimens (VEN) have been widely adopted as frontline therapeutic options for elderly patients with acute myeloid leukemia (AML). However, comprehensive real‐world comparisons of VEN with conventional intensive or reduced‐intensity chemotherapy remain limited.
Jiadan Sheng   +54 more
wiley   +1 more source

Extended Disease Remission Achieved With Cytarabine and Venetoclax Therapy in an Elderly Patient With a Blastic Plasmacytoid Dendritic Cell Neoplasm

open access: yesClinical Case Reports, Volume 14, Issue 11, November 2026.
ABSTRACT Blastic plasmacytoid dendritic neoplasm (BPDCN) is an aggressive and rare hematological malignancy. Treatment options for frail, elderly patients with BPDCN are limited. Herein, we report the novel use of cytarabine and venetoclax therapy in an elderly patient with BPDCN, which extended his overall survival and improved his quality of life.
Luc M. Murray‐Jones   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy